Intellia Therapeutics, Inc. (NTLA)
After hours:
| Previous close | 21.38 |
| Open | 22.60 |
| Bid | 23.47 x 200 |
| Ask | 23.52 x 200 |
| Day's range | 22.15 - 24.33 |
| 52-week range | 19.37 - 47.48 |
| Volume | |
| Avg. volume | 1,373,715 |
| Market cap | 2.269B |
| Beta (5Y monthly) | 1.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.37 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 69.61 |
Insider MonkeyIs Intellia Therapeutics, Inc. (NASDAQ:NTLA) the Most Promising Gene Therapy Stock to Buy Now?
We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss whether Intellia Therapeutics, Inc. (NASDAQ:NTLA) is the most promising gene therapy stock to buy now. Gene therapy involves treating illnesses by modifying, replacing, or supplementing faulty or missing genes responsible for a disease. This […]
GlobeNewswireIntellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
Extended follow-up data reaching over two years in the earliest patients dosed reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema (HAE)Eight of 10 patients remain completely attack-free following the 16-week primary observation period through the latest follow-up, including patients with the most severe diseaseSingle dose of NTLA-2002 led to a 98% mean reduction in monthly HAE attack rate, with an average follow-up of over 20 months across a
ZacksIntellia Therapeutics, Inc. (NTLA) Just Overtook the 50-Day Moving Average
Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?
